Actively Recruiting
A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer
Led by Celltrion · Updated on 2025-04-23
606
Participants Needed
1
Research Sites
178 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this Phase 3 clinical trial is to compare efficacy and safety of CT-P51 and European Union (EU) approved Keytruda in combination with platinum pemetrexed chemotherapy in patients with previously untreated metastatic nsNSCLC.
CONDITIONS
Official Title
A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Stage IV, non squamous non-small cell lung cancer
- No prior systemic anti-cancer therapy for metastatic NSCLC
- At least 1 measurable lesion as per RECIST version 1.1
You will not qualify if you...
- Predominantly squamous cell histology NSCLC
- Hypersensitivity or contraindication to any component of the study drug, pemetrexed, cisplatin, or carboplatin
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
ltd "Institute of Clinical Oncology"
Tbilisi, Georgia
Actively Recruiting
Research Team
J
Jaeyoung Jang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here